Oppenheimer Begins Coverage on Jazz Pharmaceuticals (NASDAQ:JAZZ)

Oppenheimer started coverage on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a research note released on Thursday morning, The Fly reports. The brokerage issued an outperform rating on the specialty pharmaceutical company’s stock.

A number of other equities analysts also recently weighed in on JAZZ. Wells Fargo & Co lowered their target price on shares of Jazz Pharmaceuticals from $189.00 to $162.00 and set an overweight rating for the company in a research note on Thursday, April 30th. Jefferies Financial Group started coverage on shares of Jazz Pharmaceuticals in a research note on Monday, April 6th. They set a buy rating and a $149.00 target price for the company. BMO Capital Markets lowered their target price on shares of Jazz Pharmaceuticals from $205.00 to $193.00 and set an outperform rating for the company in a research note on Wednesday, May 6th. Wolfe Research raised shares of Jazz Pharmaceuticals from a peer perform rating to an outperform rating in a research note on Tuesday, July 28th. Finally, SVB Leerink lifted their target price on shares of Jazz Pharmaceuticals from $160.00 to $169.00 and gave the stock an outperform rating in a research note on Monday, June 1st. Two analysts have rated the stock with a sell rating, five have given a hold rating and fifteen have given a buy rating to the company. Jazz Pharmaceuticals presently has an average rating of Buy and a consensus target price of $157.17.

Shares of JAZZ stock traded down $5.52 during trading hours on Thursday, hitting $108.25. 900,755 shares of the company’s stock traded hands, compared to its average volume of 484,911. The stock’s 50 day simple moving average is $109.68 and its 200 day simple moving average is $117.54. The stock has a market cap of $5.99 billion, a PE ratio of 22.51, a price-to-earnings-growth ratio of 1.33 and a beta of 1.23. Jazz Pharmaceuticals has a 12 month low of $86.88 and a 12 month high of $154.24. The company has a quick ratio of 3.62, a current ratio of 3.83 and a debt-to-equity ratio of 0.61.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, May 5th. The specialty pharmaceutical company reported $0.45 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.21 by $0.24. The firm had revenue of $534.73 million during the quarter, compared to the consensus estimate of $544.55 million. Jazz Pharmaceuticals had a net margin of 12.81% and a return on equity of 21.66%. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter last year, the firm earned $3.67 earnings per share. As a group, equities research analysts expect that Jazz Pharmaceuticals will post 9.82 EPS for the current fiscal year.

In other Jazz Pharmaceuticals news, Director Seamus Mulligan acquired 50,000 shares of Jazz Pharmaceuticals stock in a transaction dated Wednesday, May 27th. The stock was purchased at an average cost of $117.31 per share, for a total transaction of $5,865,500.00. Following the completion of the acquisition, the director now directly owns 1,117,788 shares of the company’s stock, valued at $131,127,710.28. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 4.60% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Nissay Asset Management Corp Japan ADV lifted its position in shares of Jazz Pharmaceuticals by 2.2% during the first quarter. Nissay Asset Management Corp Japan ADV now owns 5,734 shares of the specialty pharmaceutical company’s stock valued at $572,000 after purchasing an additional 121 shares in the last quarter. RDL Financial Inc. lifted its position in shares of Jazz Pharmaceuticals by 1.5% during the first quarter. RDL Financial Inc. now owns 8,700 shares of the specialty pharmaceutical company’s stock valued at $868,000 after purchasing an additional 129 shares in the last quarter. Cardan Capital Partners LLC lifted its position in shares of Jazz Pharmaceuticals by 0.7% during the second quarter. Cardan Capital Partners LLC now owns 19,758 shares of the specialty pharmaceutical company’s stock valued at $2,180,000 after purchasing an additional 132 shares in the last quarter. Signaturefd LLC lifted its position in shares of Jazz Pharmaceuticals by 106.3% during the first quarter. Signaturefd LLC now owns 260 shares of the specialty pharmaceutical company’s stock valued at $26,000 after purchasing an additional 134 shares in the last quarter. Finally, Squar Milner Financial Services LLC raised its position in Jazz Pharmaceuticals by 25.0% in the first quarter. Squar Milner Financial Services LLC now owns 765 shares of the specialty pharmaceutical company’s stock worth $76,000 after acquiring an additional 153 shares during the period. 89.01% of the stock is currently owned by institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

See Also: Beige Book

The Fly

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.